Related Experiment Videos

The effect of rapamycin on c-jun expression in human lymphocytes

X Shan1, H Luo, H Chen

  • 1Laboratory of Nephrology and Transplantation Immunology, Notre-Dame Hospital Research Center, Montreal, Quebec, Canada.

Insights

Rapamycin (RAPA) inhibits early T cell activation by blocking c-jun gene expression. However, c-jun

Area of Science:

  • Immunology
  • Molecular Biology
  • Cellular Biology

Background:

  • Rapamycin (RAPA) is a known immunosuppressant drug.
  • Previous studies suggest RAPA affects lymphocyte activation late in the G1 phase.

Purpose of the Study:

  • To investigate the effect of RAPA on the expression of the immediate early gene c-jun in human T cells.
  • To explore the role of c-jun in lymphocyte activation cascades.

Main Methods:

  • Human T cells were stimulated with PHA.
  • The expression of c-jun was measured following RAPA treatment.
  • Ouabain, a Na+/K+ ATPase inhibitor, was used to induce late c-jun expression.
  • Sensitivity of induced c-jun expression to RAPA and cyclosporin A (CsA) was assessed.

Main Results:

  • RAPA significantly inhibited PHA-induced c-jun expression in human T cells.
  • Ouabain induced a late c-jun expression (16 hours post-stimulation).
  • Late c-jun expression induced by ouabain was sensitive to CsA but not RAPA.

Conclusions:

  • RAPA interacts with the lymphocyte activation cascade at a very early stage by inhibiting c-jun expression.
  • The role of c-jun in lymphocyte activation extends beyond the early phase, as evidenced by CsA-sensitive, RAPA-insensitive late expression.

Related Concept Videos